article_metadata: James Luke Godwin Shuchie Jaggi Imali Sirisena Pankaj Sharda Ajay D Rao Ranee Mehra Colleen Veloski
article_metadata: 10.1186/s40425-017-0245-2
article_metadata: J Immunother Cancer
article_metadata: 2017 May 16;5:40.
article_metadata: autoimmune diabetes diabetic ketoacidosis (dka) immune related adverse events (irae) nivolumab non-small cell lung cancer (nsclc) pd-1 inhibitor
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/28515940/
article_metadata: Adenocarcinoma / secondary Antibodies, Monoclonal / adverse effects Antineoplastic Agents / adverse effects Diabetes Mellitus, Type 1 / chemically induced Diabetic Ketoacidosis / chemically induced Lung Neoplasms / drug therapy
article_metadata: Adenocarcinoma / secondary Antibodies, Monoclonal / adverse effects Antineoplastic Agents / adverse effects Diabetes Mellitus, Type 1 / chemically induced Diabetic Ketoacidosis / chemically induced Lung Neoplasms / drug therapy Case Reports Adenocarcinoma / drug therapy Adult Female Humans Nivolumab Programmed Cell Death 1 Receptor / antagonists & inhibitors Antibodies, Monoclonal Antineoplastic Agents PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab
article_metadata: PMC5433051
article_metadata: 28515940
article_metadata: Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
article_metadata: 2017